SSP
IMMU

Sapphire Star Partners’s Immunomedics Inc IMMU Stock Holding History

Sapphire Star Partners’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-20,000
Closed -$323K – 123
2017
Q4 		$323K Buy
+20,000
New +$236K 0.38% 90

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Sapphire Star Partners's IMMU Position: Q1 2018 in Review

Sapphire Star Partners sold out of Immunomedics Inc (IMMU) in Q1 2018, closing a stake of 20,000 shares — an estimated $323K sold.

Sapphire Star Partners first reported a position in IMMU in Q4 2017 and held it in 1 quarter. The position peaked at $323K in Q4 2017. 168 funds tracked by Wall St. Rank hold IMMU as of Q1 2018.

  • Sapphire Star Partners reported no remaining Immunomedics Inc position as of Q1 2018 after selling out during the quarter.
  • Sapphire Star Partners sold 20,000 Immunomedics Inc shares in Q1 2018, an estimated $323K.
  • Sapphire Star Partners first reported a position in Immunomedics Inc in Q4 2017 and held it in 1 quarter.
  • Sapphire Star Partners's Immunomedics Inc position peaked at $323K in Q4 2017.
  • 168 funds tracked by Wall St. Rank held Immunomedics Inc as of Q1 2018.

Based on Sapphire Star Partners's 13F filing for Q1 2018, filed 10 May 2018.